Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D. Ignatiadis M, et al. J Clin Oncol. 2007 Nov 20;25(33):5194-202. doi: 10.1200/JCO.2007.11.7762. Epub 2007 Oct 22. J Clin Oncol. 2007. PMID: 17954712
Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer.
Ignatiadis M, Perraki M, Apostolaki S, Politaki E, Xenidis N, Kafousi M, Stathopoulos E, Lianidou E, Sotiriou C, Georgoulias V, Mavroudis D. Ignatiadis M, et al. Clin Breast Cancer. 2007 Dec;7(11):883-9. doi: 10.3816/CBC.2007.n.054. Clin Breast Cancer. 2007. PMID: 18269779
Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.
Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulias V, Mavroudis D. Ignatiadis M, et al. Clin Cancer Res. 2008 May 1;14(9):2593-600. doi: 10.1158/1078-0432.CCR-07-4758. Clin Cancer Res. 2008. PMID: 18451221
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.
Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schütz F, Goldstein DR, Piccart M, Delorenzi M. Wirapati P, et al. Among authors: ignatiadis m. Breast Cancer Res. 2008;10(4):R65. doi: 10.1186/bcr2124. Epub 2008 Jul 28. Breast Cancer Res. 2008. PMID: 18662380 Free PMC article.
HER-2 as a target for breast cancer therapy.
Ignatiadis M, Desmedt C, Sotiriou C, de Azambuja E, Piccart M. Ignatiadis M, et al. Clin Cancer Res. 2009 Mar 15;15(6):1848-52. doi: 10.1158/1078-0432.CCR-08-1844. Clin Cancer Res. 2009. PMID: 19289395 Free article. No abstract available.
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors.
McBride DJ, Orpana AK, Sotiriou C, Joensuu H, Stephens PJ, Mudie LJ, Hämäläinen E, Stebbings LA, Andersson LC, Flanagan AM, Durbecq V, Ignatiadis M, Kallioniemi O, Heckman CA, Alitalo K, Edgren H, Futreal PA, Stratton MR, Campbell PJ. McBride DJ, et al. Among authors: ignatiadis m. Genes Chromosomes Cancer. 2010 Nov;49(11):1062-9. doi: 10.1002/gcc.20815. Genes Chromosomes Cancer. 2010. PMID: 20725990 Free PMC article.
134 results